4.4 Article

Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study

Journal

JOURNAL OF CLINICAL SLEEP MEDICINE
Volume 11, Issue 11, Pages 1273-+

Publisher

AMER ACAD SLEEP MEDICINE
DOI: 10.5664/jcsm.5184

Keywords

biomarker; EMG activity; polysomnography; REM sleep behavior disorder; SINBAR

Funding

  1. Oesterreichische Nationalbank (Austria's central bank, Anniversary Fund) [15127]
  2. UCB [15127]
  3. Mundipharma, Respironics
  4. AbbVie
  5. Allergan
  6. Astra-Zeneca
  7. BIAL
  8. Boehringer-Ingelheim
  9. Boston Scientific
  10. GlaxoSmithKline
  11. Ipsen
  12. Lund-beck
  13. Medtronic
  14. MSD
  15. Merck-Serono
  16. Merz
  17. Novartis
  18. OrionPharma
  19. Teva

Ask authors/readers for more resources

Study Objectives: Idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) is a harbinger of synuclein-mediated neurodegenerative diseases. It is unknown if this also applies to isolated REM sleep without atonia (RWA). We performed a long-term follow-up investigation of subjects with isolated RWA. Methods: Participants were recruited from 50 subjects with isolated RWA who were identified at the sleep laboratory of the Department of Neurology at the Medical University of Innsbruck between 2003 and 2005. Eligible subjects underwent follow-up clinical examination, polysomnography, and assessment of neurodegenerative biomarkers (cognitive impairment, finger speed deficit, impaired color vision, olfactory dysfunction, orthostatic hypotension, and substantia nigra hyperechogenicity). Results: After a mean of 8.6 +/- 0.9 y, 1 of 14 participating subjects (7.3%) progressed to RBD. Ten of 14 RWA subjects (71.4%) were positive for at least one neurodegenerative biomarker. Substantia nigra hyperechogenicity and presence of mild cognitive impairment were both present in 4 of 14 subjects with isolated RWA. Electromyographic activity measures increased significantly from baseline to follow-up polysomnography (any mentalis and both anterior tibialis muscles: 32.5 +/- 9.4 versus 52.2 +/- 16.6%; p = 0.004). Conclusion: This study provides first evidence that isolated RWA is an early biomarker of synuclein-mediated neurodegeneration. These results will have to be replicated in larger studies with longer observational periods. If confirmed, these disease findings have implications for defining at-risk cohorts for Parkinson disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available